there is no agreement yet regarding the role of ZIKV in other neurological disorders in adults, there are early observations which may suggest such possibility. This review summarizes the current evidence that supports the association between ZIKV infection and neurological disease in the adult.
Methods
We conducted a search of articles on ZIKV published up until , in public electronic databases, including PubMed and the surveillance system of the World Health Organization (WHO), the Pan American Health Organization (PAHO), and the European Centre for Disease Prevention and Control (ECDC). We selected studies providing evidence on a link between ZIKV and neurological disorders in adults including GBS, encephalitis, myelitis, and other neurological syndromes. We summarized the relevant studies highlighting the evidence used to support the link to ZIKV in each one.
Results
As of June 1, 2016, PubMed listed 761 publications with the search word "Zika." After excluding review articles, comments, and editorials, we found 16 articles that provided new information about ZIKV-related neurological disease in the adult. Four surveillance reports from WHO, PAHO, and ECDC were also relevant. We included population and surveillance studies (n ¼ 7), case reports (n ¼ 9), case series (n ¼ 3), and casecontrol studies (n ¼ 1). Out of the 20 articles, 17 were related to GBS, 2 discussed a link with encephalitis/encephalopathy, and only 1 referred to myelitis. ►Table 1 summarizes the relevant studies. Articles were also included if they provided information related to possible mechanisms of ZIKV pathogenesis in the nervous system.
ZIKV and Guillain-Barré Syndrome
GBS is an acute progressive paralytic neuropathy usually preceded by a recent immune stimulation, often with sensory and cranial nerve involvement that proceeds to its peak of clinical symptoms in 2 to 4 weeks. 12, 13 Weakness pattern tends to be symmetric and develop rapidly. Cranial and autonomic nerve involvement is frequent with 20 to 30% of cases being affected with respiratory failure. 13 The incidence of GBS ranges between 0.8 and 1.9 cases per 100,000 people per year. 14, 15 The physiopathology of GBS includes an abnormal immune response targeting peripheral nerves and spinal roots generally 1 to 2 weeks after a preceding infection, out of which the best characterized organism is Campylobacter jejuni, described to have molecular mimicry with peripheral nerve antigens.
12,13,15
The observation of temporal occurrence of GBS cases during ZIKV infection outbreaks has pointed toward a possible relationship of such infection with the development of GBS. During a ZIKV infection outbreak in French Polynesia in 2013, 26 cases of GBS were initially reported over the course of 8 weeks, exceeding the GBS baseline incidence estimated to be 3 to 8 cases per year.
3
A similar temporal pattern of increase of GBS cases has been documented since 2015 in some countries in the Americas affected by the ongoing ZIKV outbreak. 
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During the epidemic in French Polynesia in 2013, a total of 42 cases of GBS were diagnosed 4, 26 and analyzed retrospectively in a case-control study. 27 ZIKV diagnosis was done based on serology assays. Out of the 42, 88% reported history of a viral syndrome compatible with ZIKV infection, with a median of 6 days before the neurological symptoms. GBS was characterized by a rapid progression pattern and a high frequency of facial palsy (64%). An acute motor axonal neuropathy subtype of GBS was found by electrophysiology testing. Seroprevalence for antiflavivirus antibodies was significantly different between the GBS group and the control group 1 (nonfebrile illness population). The resulting association measure (odds ratio) between ZIKV infection exposure and GBS was 59.7 (95% confidence interval: 10.4-1). None of the GBS cases were ZIKV RT-PCR positive. Dengue virus (DENV) immunoglobulin M (IgM) was positive in 19% of GBS cases where ZIKV-IgM was also positive; those were considered positive for recent ZIKV infection as DENV positivity was related with cross-reactivity.
27
The French Polynesia case-control study provided the highest level of epidemiological evidence to date of a link between ZIKV and GBS. Surveillance data describing a temporal correlation of ZIKV and GBS cases also support the association. However, well-designed controlled studies with stronger and consistent results are required to demonstrate a causal relationship. In addition, caution must be exercised when interpreting serology results in regions of the world with high incidence and circulation of DENV or other flaviviruses, as there is known cross-reactivity of antiflavivirus antibodies. Even plaque reduction neutralization testing cannot reliably establish the difference. Currently, the only way to accurately diagnose ZIKV infection is through detection of RNA genome using RT-PCR techniques.
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ZIKV and Encephalitis/Encephalopathy
Encephalopathy refers to a clinical state of altered mental status or other cognitive impairment with or without brain 
ZIKV and Myelitis
Myelitis is a focal inflammatory disorder of the spinal cord resulting in motor, sensory, and autonomic dysfunction.
32
There has been limited information regarding myelitis as a possible complication of ZIKV. In the initial reports from the surveillance system in Brazil, Araujo et al 8 described two cases of acute demyelinating encephalomyelitis with positive detection of ZIKV by RT-PCR in the state of Pernambuco (2015) . Clinical profile and imaging were not reported, as well as the type of biological sample used for ZIKV testing. There has been only one case reported of myelitis associated with ZIKV that is fully characterized. It corresponds to a 15-year-old woman from Guadeloupe 33 with a prodromal syndrome of headaches and conjunctivitis for 7 days followed by left hemiparesis and paresthesia, urinary retention, and a T4 sensory bilateral level. Lesions were demonstrated in the cervical and thoracic spinal cord by MRI in T2-weighted images. Electromyographic and CSF analysis were normal. ZIKV was detected in serum, urine, and CSF by RT-PCR on the second day of admission. She improved with methylprednisolone 1 g daily for 5 days and was able to walk unaided after such treatment.
It is unclear if there are more myelitis cases that are not being reported or described in detail. The association of ZIKV with myelitis is still presumptive.
ZIKV and Other Neurological Complications
In the surveillance systems scrutinized, there are few reports of other neurological syndromes associated with ZIKV that are not fully characterized including isolated facial paralysis 4 (French Polynesia, 2014) and cerebellitis 11 (Panama, 2016).
Evidence for ZIKV Infection and Neuropathogenesis in Adults
Early experiments with animal models of infection were performed soon after the ZIKV was discovered. In 1952, Dick 34 described the pathological properties of ZIKV. The virus showed a high degree of neurotropism in the brain of young mice when directly inoculated causing degeneration of the neural cells, mainly at the hippocampus. Later, Bell et al 35 described the impact of ZIKV infection in the developing mouse brain. The virus infected both neurons and astrocytes causing marked glial activation; a special predilection for the pyriform cells in the hippocampus was remarkable. Intracytoplasmic inclusions consistent with autophagy vesicles were described in ZIKV infected neurons as a mechanism upregulating ZIKV replication in vitro.
35-37
Recently, murine models of ZIKV infection during pregnancy have further supported the neurotropism. Fetuses of ZIKV infected mothers have shown ZIKV infection in the brain which lead to intrauterine growth restriction-like syndrome 38 and microcephaly. 39, 40 Further experiments with human-derived induced pluripotent stem cells (iPSC) modeled neurospheres suggest that the target of ZIKV infection is neuronal progenitor cell population in which the virus induced cell death and impaired neurodevelopment.
41,42
The adult animal models on ZIKV neurotropism have involved either direct brain viral inoculation or the use of knockout mice. So far, there are no experimental studies recapitulating the natural course of infection that demonstrates ZIKV neurotropism in adults. However, the detection of the virus by RT-PCR in CSF, the proven replicative capacity of isolated virus in cell cultures, and the high titers of anti-ZIKV antibodies in CSF of infected people, as described earlier, support the neurotropism of ZIKV as a potential explanation for neurological complications. Despite causality criteria still need to be fulfilled, the determination of a link between ZIKV with neurological disorders in adults specially GBS has come from various lines of evidence which together support a potential causal association.
43
Mechanisms of ZIKV-Related Guillain-Barré Syndrome in the Adult
ZIKV infection appears to be a critical mechanism in the pathogenesis of GBS cases observed during recent outbreaks in the Americas and other areas of the world affected by mosquito-borne flaviviruses (►Fig. 1). Despite the growing evidence of association of ZIKV infection with GBS, there is still uncertainty about the mechanisms involved in pathogenesis. Classically, GBS is thought of as being immune mediated involving both cellular and humoral immune responses. 44 One of the main postulated pathogenic mechanisms is molecular mimicry between certain pathogens and the peripheral nervous system. 13 In the case of ZIKV-related GBS, several hypotheses including molecular mimicry have been postulated as possible pathogenic mechanisms. ZIKV polyprotein has been shown to resemble human proteins linked to myelination, axonal function, and neurodevelopment. 45 Therefore, ZIKV-induced neutralizing antibodies may cross-react with the peripheral nerve proteins resulting in an immune-mediated damage (►Fig. 1a). 45 However, ZIKV infection could trigger GBS by other suggested mechanisms. As described for DENV, antibody-mediated enhancement (ADE) of ZIKV infection is believed a potential mechanism associated with ZIKV neurological complications. Despite genetic difference between ZIKV and DENV by around 40%, a high neutralizing antibodies cross-reactivity between them has been demonstrated. 46 In regions of the world affected by the recent ZIKV outbreaks and where DENV is endemic, immunological memory response against DENV may enhance ZIKV replication by ADE mechanism which may lead to complications such as GBS (►Fig. 1b) and eventually, a subsequent amplification of antigenic viral stimulation to the immune system in the form of a secondary flavivirus infection. Another hypothetical mechanism may involve T cell responses triggered by ZIKV which may target neural, axonal, myelin, or Schwan cell antigens (►Fig. 1c). This hypothesis is derived from observation of perineural T cell infiltrates in nerve tissues from autopsies of GBS cases associated with other pathogens, which support the role of a cell-mediated immunity in GBS. 47 Similarly, as seen in DENV, ZIKV might induce a polyclonal B lymphocytes activation contributing to an exacerbated immune response involving the nervous system. 48 Besides the indirect effect of ZIKV in pathogenesis of neurological disease through the immune system, a direct neurotropic pathogenic damage of the peripheral nervous system has also been proposed. Direct viral effect on neurons or glial cells may be a possible mechanism in cases of encephalitis, myelitis, or even GBS although such evidence is scarce and based only on observations in experimental mouse (►Fig. 1d). 35, 39 An overlap between immune-mediated and direct-viral mechanisms is plausible, but the lack of neuropathological evidence from human biopsy or autopsy study hinders any conclusion on such possibility. Since none of these postulations have been elucidated, further research efforts are required for a comprehensive understanding of the neuropathogenic mechanisms of ZIKV infection in the adult central and peripheral nervous system. Viral, host, and environmental factors will need to be included also in future studies of such mechanisms.
Conclusion
The spectrum of ZIKV-related neurological complications is still unknown; however, GBS, encephalitis, and myelitis have been linked to recent ZIKV outbreaks. One case-control study described earlier provides the highest support toward linking ZIKV with GBS. Most available data are derived from epidemiological surveillance systems regarding temporal relationship of GBS clusters during ZIKV epidemics, as well as case reports of patients with encephalitis or myelitis along with ZIKV detection in biological samples. With the limited current evidence, causality cannot yet be established to link ZIKV with neurological disorders in adults. Mechanisms underlying the potential pathophysiology of ZIKV in the nervous system are still unclear. Global action needs to be taken to drive well-designed prospective studies to evaluate such relationship; meanwhile, health authorities should be aware of the potential risks of neurological disorders derived from ZIKV infection such as GBS, encephalitis, and myelitis.
